ҩʦ¸ÉÔ¤¶Ô2ÐÍÌÇÄò²¡»¼ÕßÁÙ´²½á¾ÖÓ°ÏìµÄmeta·ÖÎö
ÒìÖÊÐÔ,ÎÄÏ×,1×ÊÁÏÓë·½·¨,1¼ìË÷²ßÂÔ,2ÄÉÈë±ê×¼,3Åųý±ê×¼,4ÎÄÏ×ɸѡÓë×ÊÁÏÌáÈ¡,5ÄÉÈëÑо¿µÄÆ«ÒзçÏÕ·ÖÎö,6ͳ¼ÆÑ§·½·¨,2½á¹û,1ÎÄÏ×ɸѡ½á¹û,2ÄÉÈëÎÄÏ׵Ļù±¾ÌØÕ÷ÓëÖÊÁ¿ÆÀ¼Û,3¸ÉÔ¤´ëÊ©,4Meta·ÖÎö
Àî½Ü£¬³ÂÏþ·Æ£¬ÕÅÎÀ£¬Ê©Ïþ»Ü£¬ÄßÀÚ£¬½¯Ö¾ÌΣ¬Ðì×Óº®£¬Áø´ºæ·(ÕżҸÛÊÐÖÐҽҽԺҩѧ²¿£¬½ËÕ ÕÅ¼Ò¸Û 215600)2 ÐÍÌÇÄò²¡(type 2 diabetes patients£¬T2DM)ÊÇÒ»×éÒòÒȵºËØ·ÖÃÚ²»×ã»òÒȵºËصֿ¹£¬ÒÔ¸ßѪÌÇÎªÌØÕ÷µÄ´úлÐÔ¼²²¡¡£2019ÄêÎÒ¹úµÄÌÇÄò²¡ÈËÊýÒÑ´ïµ½1.164 ÒÚ£¬Î»¾ÓÈ«ÇòµÚÒ»[1]¡£ÌÇÄò²¡¼°²¢Æä·¢Ö¢²»½ö½µµÍÁË»¼ÕßÉú»îÖÊÁ¿£¬Ôö¼ÓÁËÒ½ÁÆ·ÑÓÃÖ§³ö£¬¸ü¸øÎÒ¹úµÄÎÀÉú×ÊÔ´´øÀ´Á˾޴óѹÁ¦[2]¡£¼øÓÚÌÇÄò²¡µÄ¼²²¡ÌØÕ÷£¬×îаæÖйú2 ÐÍÌÇÄò²¡·ÀÖÎÖ¸ÄÏÖ¸³öÒÔҽʦ¡¢»¤Ê¦¡¢ÓªÑøÊ¦¡¢Ô˶¯Ê¦ÎªÖ÷µÄ¶àѧ¿Æ¹ÜÀíÍŶÓÄܹ»´Ó¶àά¶ÈÓÐЧ¿ØÖÆÑªÌDz¢ÑÓ»º²¢·¢Ö¢·¢Éú£¬µ«²¢Î´¹Ø×¢Ò©Ê¦µÄ×÷ÓÃ[3]¡£¶àÏîÑо¿ÏÔʾ£¬Ò©Ê¦¿Éͨ¹ý½â¾ö»¼ÕßµÄÒ©ÎïÏà¹ØÎÊÌâ(drug related problems£¬DRP)¡¢Ç¿»¯»¼Õß¹ØÓÚÌÇÄò²¡ÖªÊ¶µÄ¼ÇÒä¡¢Ìá¸ß»¼ÕßÓÃÒ©ÒÀ´ÓÐԵȷ½Ê½£¬¸Ä±ä»¼ÕßѪÌÇ¿ØÖƲ»¼ÑµÄ×´¿ö[4-5]¡£±¾ÎÄÖ¼ÔÚÆÀ¼Û¹úÄÚÍâҩʦ¶Ô2 ÐÍÌÇÄò²¡»¼Õß½øÐиÉÔ¤µÄÁÙ´²ÁÆÐ§£¬´Ó¶øÆÀ¼Ûҩʦ×÷Ϊ¶àѧ¿Æ¹ÜÀíÍŶÓÖеÄÒ»Ô±ÔÚÌÇÄò²¡¹ÜÀíÖз¢»ÓµÄÖØÒª×÷Óá£
1 ×ÊÁÏÓë·½·¨
1.1 ¼ìË÷²ßÂÔ
¼ÆËã»ú¼ìË÷PubMed¡¢Cochrane Library¡¢Web of Science¡¢Embase¡¢ÖªÍø¡¢Íò·½¡¢Î¬ÆÕµÈÊý¾Ý¿â¡£¼ìË÷ʱÏÞ¾ùΪ2000Äê1Ô¡ª2021Äê8Ô¡£ÖÐÎļìË÷´ÊΪ¡°Ò©Ê¦¡±¡°ÁÙ´²Ò©Ê¦¡±¡°2 ÐÍÌÇÄò²¡¡±¡°¸ÉÔ¤¡±¡°¹ÜÀí¡±£»Ó¢ÎļìË÷´ÊΪ¡°Pharmacist¡±¡°Clinical Pharmacist¡±¡°Diabetes type 2¡±¡°Diabetes mellitus type 2¡±¡°Type 2 diabetes¡±¡°Intervention¡±¡°Management¡±¡£
1.2 ÄÉÈë±ê×¼
¢Ù Ñо¿¶ÔÏó£ºÈ·Õï2 ÐÍÌÇÄò²¡µÄ»¼Õߣ»¢ÚÑо¿ÀàÐÍ£ºËæ»ú¶ÔÕÕÊÔÑé(randomized controlled trial£¬RCT)£»¢Û Ö÷Òª½á¾ÖÖ¸±ê£ºÌÇ»¯Ñªºìµ°°×(HbA1c)£»¢Ü ´ÎÒª½á¾ÖÖ¸±ê£º¿Õ¸¹ÑªÌÇ(FBG)¡¢ÑªÌÇ´ï±êÂÊ(HbA1c <7%)¡¢ÊÕËõѹ(SBP)¡¢ÊæÕÅѹ(DBP)¡¢×ܵ¨¹Ì´¼(TC)¡¢Èýõ£¸ÊÓÍ(TG)¡¢µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼(LDL-C)¡¢¸ßÃܶÈÖ¬µ°°×µ¨¹Ì´¼(HDL-C)¡¢ÌåÖÊÁ¿Ö¸Êý(BMI)¡¢ÓÃÒ©ÒÀ´ÓÐԵȡ£
1.3 Åųý±ê×¼
¢Ù ·ÇËæ»ú¶ÔÕÕÊÔÑ飻¢Ú 䱨¸æ½á¾ÖÖ¸±êµÄÑо¿£»¢Û ·ÇÓ¢ÎÄ¡¢·ÇÖÐÎÄ·¢±íµÄÑо¿£»¢Ü ×ÛÊö¡¢»Ø¹ËÐÔÑо¿¡¢²¡Àý±¨¸æ¡¢ÁÙ´²ÊÔÑéÑо¿£»¢Ý ÎÞ·¨»ñÈ¡ÔÎĵÄÑо¿£»¢Þ ÈÑÉïÌÇÄò²¡»òÌÇÄò²¡ºÏ²¢ÈÑÉﻼÕß ......
ÄúÏÖÔڲ鿴ÊÇÕªÒªÒ³£¬È«Îij¤ 15646 ×Ö·û¡£